Patel Naimish 4

What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), received a grant of 22,000 restricted stock units (RSUs) on May 29, 2026. The RSUs were granted at a $0.00 price (derivative award) and represent a contingent right to receive one share of CRSP common stock per unit upon vesting.

Key Details

• Transaction type/date: Award (code A) on 2026-05-29; filing dated 2026-06-02.
• Amount/price: 22,000 RSUs granted at $0.00 (no cash purchase).
• Vesting: 100% of the award vests on November 29, 2028 (per footnote).
• Derivative note: Each RSU equals a right to one common share upon vesting (footnote F1).
• Shares owned after transaction: Not specified in the excerpted filing.
• Timeliness: The Form 4 was filed June 2, 2026 for the May 29 grant; no late filing flag is indicated in the filing excerpt.

Context
RSU grants are a common form of executive compensation designed to align management incentives with shareholder value; they do not represent immediately tradeable shares until they vest. This award is a grant (not a purchase or sale) and therefore should not be interpreted as a near-term market sentiment signal.